Of particular importance, preclinical and clinical trials using FN1-guided cancer therapies, e.g., the extra domain A and B (EDA/B) of FN1 variants specific to tumor, are areas of active investigation [21,48]. This evidence concerns the gene FN1 and neoplasm.